France’s Ipsen has presented its full-year 2007 figures which show that revenues rose 5.1% to 993.8 million euros, while operating income was up 11.6% to 208.9 million euros. Net profit increased 4.6% to 150.6 million euros.

Ipsen noted that the revenue rise was driven by sales of Decapeptyl (triptorelin pamoate) for prostate cancer, its Somatuline (lanreotide) range of drugs for acromegaly and neuroendocrine tumours and Dysport (botulinum toxin type A) for wrinkles. The firm’s chief executive Jean-Luc Belingard said that the group's performance in 2007 “is in line with our objectives despite a difficult environment marked by sustained price pressure and increased competition, notably in France".

The company said that it is targeting underlying sales growth of 6.5%-7.5% for 2008 and an operating margin of between 22%-23% of sales. Mr Belingard added that in 2008, “we will pursue our entry into the North American market and will reinforce our portfolio of products”.

He added that the recent publication of clinical results, such as the impressive Phase III data for the prostate cancer drug Acapodene (toremifene), plusresearch a Phase II update “for our GLP-1 analogue partnered with Roche or Phase I [data] for our promising anti-tumour agent STX-64, will confirm Ipsen’s strong R&D capabilities”.